Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 281

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 7
Chunk 281
---
 and Life Sciences segments, contributed to the year-over-year flat core sales growth in developed markets.  For the same period, sales in high-growth markets decreased year-over-year by 4% and core sales in high-growth markets decreased at a mid-single digit rate, due primarily to low double-digit core revenue declines in China.  The decline in core sales in high-growth markets was primarily driven by lower demand across all segments, due to weakness in capital spending and generally lower underlying activity levels.  High-growth markets represented approximately 29% of the Company’s total sales in 2024.

The Company’s net earnings from continuing operations for the year ended December 31, 2024 totaled approximately $3.9 billion, compared to approximately $4.2 billion for the year ended December 31, 2023.  Net earnings attributable to common stockholders for the year ended December 31, 2024 totaled approximately $3.9 billion or $5.29 per diluted common share compared to approximately $4.7 billion or $6.38 per diluted common share for the year ended December 31, 2023.  2024 intangible asset impairments and increased operating expenses, net of increased other income, drove the year-over-year decline in net earnings from continuing operations and diluted net earnings per common share from continuing operations.  In addition to the above factors, net earnings from discontinued operations for 2024 compared with 2023 contributed to the lower net earnings attributable to common stockholders in 2024.  Refer to “—Results of Operations” for further discussion of the year-over-year changes in net earnings and diluted net earnings per common share for the years ended December 31, 2024 and 2023.  In response to current economic conditions, the Company expects to review and adjust its cost structure.  In the first quarter of 2025, the Company commenced an initiative to identify productivity improvement and cost savings opportunities that we anticipate would generate annual pre-tax savings of at least $150 million.  The Company expects these opportunities to be broad-based, including opportunities within China and the Diagnostics segment.

Acquisitions 

During 2024, the Company acquired 3 businesses for total consideration of $558 million in cash, net of cash acquired.  The businesses acquired complement existing units of the Company’s Life Sciences segment.  The Company preliminarily recorded an aggregate of $305 million of goodwill related to these acquisitions.  

Refer to Note 2 to the Consolidated Financial